Novel Screening Strategies for Scleroderma PAH
| Status: | Recruiting |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), High Blood Pressure (Hypertension), Skin and Soft Tissue Infections, Dermatology, Dermatology, Dermatology |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 30 - Any |
| Updated: | 9/20/2018 |
| Start Date: | October 2013 |
| End Date: | October 2020 |
| Contact: | Ann Johnson, BSN |
| Email: | cvc-ph-research@med.umich.edu |
| Phone: | 866-963-3587 |
Patients with scleroderma can develop heart failure due to high blood pressure in the lungs
(a condition called pulmonary arterial hypertension). It is important to find pulmonary
arterial hypertension early, so that it can be treated before heart failure develops.
However, the tests that we now use to find the earliest form of this disease in scleroderma
patients are not good enough. This study will examine whether tests performed during exercise
can improve our ability to find early pulmonary arterial hypertension. The study will also
try to identify genes that are responsible for the development of pulmonary arterial
hypertension.
(a condition called pulmonary arterial hypertension). It is important to find pulmonary
arterial hypertension early, so that it can be treated before heart failure develops.
However, the tests that we now use to find the earliest form of this disease in scleroderma
patients are not good enough. This study will examine whether tests performed during exercise
can improve our ability to find early pulmonary arterial hypertension. The study will also
try to identify genes that are responsible for the development of pulmonary arterial
hypertension.
Inclusion Criteria:
- 30 years or older;
- diagnosis of limited or diffuse scleroderma (American College of Rheumatology
criteria)
- for the "high risk" group, one of the following features:
- resting transthoracic echocardiogram showing elevated right-sided pressures
within previous 3 months [tricuspid regurgitation (TR) jet >2.8 m/s or evidence
of right ventricular dysfunction]
- pulmonary function testing (PFT) showing abnormal diffusing capacity of carbon
monoxide (DLCO) not due to significant interstitial lung disease (DLCO<60%
predicted or FVC: DLCO ratio >1.4)
Exclusion Criteria:
- Pregnancy
- prior diagnosis of pulmonary hypertension
- treatment with endothelin receptor antagonists, phosphodiesterase-5 inhibitors, or
prostacyclin analogues
- previous diagnosis of obstructive lung disease or pulmonary thromboembolic disease
- current smoker
- significant valvular disease
- resting echocardiogram showing left ventricular ejection fraction<50% within previous
3 months
- resting echocardiogram showing significant (greater than Grade I) diastolic
dysfunction
- pulmonary emboli (past or present).
We found this trial at
1
site
500 S State St
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: Scott Visovatti, MD
Phone: 866-963-3587
University of Michigan The University of Michigan was founded in 1817 as one of the...
Click here to add this to my saved trials
